MARKET

DTCFF

DTCFF

Defence Therapeu
OTCMQB
0.363
NaN%
Closed 09:30 09/03 EDT
OPEN
--
PREV CLOSE
0.385
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.779
52 WEEK LOW
0.253
MARKET CAP
20.78M
P/E (TTM)
-4.5256
1D
5D
1M
3M
1Y
5Y
1D
Defence Therapeutics Broadens Radiopharmaceutical Strategy with Alpha and Beta Isotope Programs
TipRanks · 3d ago
Weekly Report: what happened at DTCFF last week (0824-0828)?
Weekly Report · 3d ago
Weekly Report: what happened at DTCFF last week (0817-0821)?
Weekly Report · 08/24 10:36
Weekly Report: what happened at DTCFF last week (0810-0814)?
Weekly Report · 08/17 10:37
Defence Therapeutics Strengthens Radiopharmaceutical Leadership with Appointment of Dr. Ryan Simms as Chief Operating Officer and Head of Radiopharmaceutical Programs
Newsfile · 08/17 07:15
Weekly Report: what happened at DTCFF last week (0803-0807)?
Weekly Report · 08/10 10:31
Defence Therapeutics Appoints Dr. Amie Phinney as President and Chief Executive Officer
Newsfile · 08/04 07:15
Weekly Report: what happened at DTCFF last week (0727-0731)?
Weekly Report · 08/03 10:30
More
About DTCFF
Defence Therapeutics Inc. is a Canada-based clinical-stage biotechnology company. The Company is engaged in developing and engineering the antibody drug conjugates (ADC) products using its proprietary platform. Its principal business activity is the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological-/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The core of its therapeutics platform is the ACCUM technology, which enables precision delivery ADCs in their intact form to target cells. The Company is focused on research, development and advancement of the main products using its Accum technology, which include ADC targeting various cancers, Anti-cancer AccuTOX program, Mesenchymal stromal cell-based vaccine (ARM-X) targeting cancer, mRNA vaccination, Cervical cancer vaccine, and Radio-immunoconjugates (RIC) targeting various cancers.

Webull offers Defence Therapeutics Inc stock information, including OTCMQB: DTCFF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DTCFF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DTCFF stock methods without spending real money on the virtual paper trading platform.